


**REMARKS**

Applicants respectfully request that the foregoing amendments be made prior to examination of the present application.

This amendment supplements the Restriction Response submitted on December 23, 2008. Due to a clerical error compound 21 was incorrectly drawn in the restriction response filed on December 23, 2008. In this Supplemental Amendment, Applicants have amended the specification on page 67, line 28 and in claims 10, 11, 19, and 20 to reflect the correct structure of Compound 21. This compound is supported by the chemical structure of Compound 21 which is described on page 68 of the specification. Because the foregoing amendments do not introduce new matter, entry thereof by the Examiner is respectfully requested. The correct structure of compound 21 is:




Claims 1-24 are pending.

**I. The Species Election Requirement and Applicants' Provisional Election**

The Examiner required election, under 35 U.S.C. § 121 and 372, between species present in claims 1-24. Office Action, pp. 2-4. The Examiner requests election between the allegedly distinct pharmaceutical composition/compound species. Office Action, p. 2.

In response, Applicants elect, **with traverse** Compound 21 as the specific and exact pharmaceutical composition/compound. Compound 21 is a compound of the formula (I) in

which X is 2-buthyn-1-yl and R3 is OH. Compound 21 is described by the following formula:



Applicants note that upon allowance of any linking claims, the restriction requirement as to the linked inventions shall be withdrawn and any claims depending from or otherwise requiring all of the limitations of the allowable linking claims will be rejoined and fully examined for patentability in accordance with 37 C.F.R. 1.104.

## **II. The Search of the Elected Sequence Is Not Unduly Burdensome**

Applicants traverse on the grounds that the claims can be searched without an undue burden. According to MPEP section 803 “if a search and examination of an entire application can be made without serious burden, the Examiner must examine it on the merits, even though it includes claims to independent and distinct inventions.” A single search conducted for the pharmaceutical compound represented by general formula (I) will provide information on all of the species. Thus, Applicants suggest examination of all the compounds listed in claims 1-24 can be made without serious burden.

**CONCLUSION**

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check or credit card payment form being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741. If any extensions of time are needed for timely acceptance of papers submitted herewith, Applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 19-0741.

Respectfully submitted,

Date December 30, 2008

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 672-5569  
Facsimile: (202) 672-5399

By 

Stephen B. Maebius  
Attorney for Applicants  
Registration No. 35,264

Benjamin A. Berkowitz  
Attorney for Applicants  
Registration No. 59,349